GHK-Cu vs KPV
Both compounds are short peptides studied for tissue-repair and inflammation-modulation endpoints, but the published mechanistic literature examines different targets in different model systems. GHK-Cu has been investigated for copper-mediated antioxidant chemistry and extracellular-matrix remodeling. KPV has been investigated for NF-κB-pathway inhibition and intestinal inflammation. This page summarises the published distinctions.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | Tripeptide-copper(II) complex (Gly-His-Lys with bound Cu²⁺) | Tripeptide (Lys-Pro-Val) derived from α-MSH C-terminal region |
| Approximate molecular weight | 402.91 g/mol (Cu-bound form) | 342.4 g/mol |
| Best-studied mechanism | Copper-mediated antioxidant chemistry; MMP and collagen expression modulation in dermal fibroblasts | NF-κB pathway inhibition; PepT1-mediated intestinal uptake |
| Primary tissues | Dermal fibroblast, keratinocyte, hair follicle, wound-bed ECM | Intestinal epithelium, colonic mucosa, skin inflammation |
| Distinctive feature | Bound copper ion is integral to the active species | Active uptake through PepT1 transporter in intestinal epithelial cells |
| Common research routes | Topical in dermatology; subcutaneous in some in-vivo studies | Intraperitoneal, oral, topical in rodent models |
| Ronin catalog vial size | 50 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
GHK-Cu has been examined through a copper-bound-tripeptide lens. The published in-vitro work reports quenching of reactive carbonyl species, modulation of integrin and p63 expression in keratinocytes, and altered MMP and collagen expression in dermal fibroblasts. The copper ion is integral to the active species. Gene-expression profiling work by Pickart and colleagues has described broad transcriptomic effects relevant to skin regeneration and antioxidant defence.
KPV is a melanocortin-derived tripeptide studied for NF-κB pathway inhibition. The Dalmasso et al. study characterised PepT1-mediated uptake in intestinal epithelial cells and demonstrated inhibition of NF-κB-driven inflammatory signalling. Subsequent work by Kannengiesser et al. confirmed anti-inflammatory activity in murine colitis models. The mechanistic frame centres on transcription-factor-level inflammatory modulation rather than extracellular-matrix remodeling.
The mechanistic profiles do not overlap. GHK-Cu operates through copper-mediated antioxidant chemistry and matrix-remodeling effects in skin and connective tissue. KPV operates through inflammatory-pathway inhibition at the NF-κB level in intestinal and inflammatory contexts. A researcher reading both literatures is reading two separate mechanistic traditions.
How research has examined each
The GHK-Cu literature spans decades of work by Pickart and colleagues on the tripeptide’s tissue-remodeling biology, including oxidative-stress chemistry, keratinocyte biology, dermal-fibroblast collagen expression, and hair-follicle research. More recent work has extended to lung-fibrosis models and zebrafish inflammation models. The compound’s copper-bound form is the active species throughout the published literature.
The KPV literature is concentrated in inflammatory bowel disease models (Dalmasso, Kannengiesser, Viennois) and in delivery-system research (Xiao nanoparticles, Sun hydrogels). The melanocortin-pathway context (KPV as a fragment of alpha-MSH) provides theoretical background, but the compound-specific mechanistic work focuses on NF-κB inhibition and PepT1-mediated uptake rather than melanocortin-receptor engagement.
Both compounds are short peptides (tripeptides in both cases) studied for tissue-related endpoints, but the tissues, the mechanisms, and the research communities are distinct. The shared territory is the broad peptide-based-repair-and-inflammation research space rather than any specific mechanistic or model-system overlap.
Stacking considerations in research contexts
Combined administration of GHK-Cu and KPV is not described in the published research. The mechanisms are unrelated, so no pharmacological collision is anticipated, but no combined-protocol data exist. Both compounds are available in the Ronin catalog at their standard vial sizes (GHK-Cu at 50 mg, KPV at 10 mg) for independent sourcing.
Sourcing both at Ronin
Both compounds in the Ronin catalog ship as lyophilised peptide in glass vials, capped and crimped, with certificate-of-analysis documentation (mass spec + HPLC purity) on the lab-results page. The GHK-Cu vial page ships at 50 mg per vial. The KPV vial page ships at 10 mg per vial. Both carry per-compound spec sheets and storage guidance. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.
Frequently asked research questions
Are GHK-Cu and KPV chemically related?
No. GHK-Cu is a copper-bound tripeptide (Gly-His-Lys-Cu2+). KPV is a melanocortin-derived tripeptide (Lys-Pro-Val). They share no sequence or mechanistic relationship.
Do they target the same tissues?
Generally not. GHK-Cu research is concentrated in skin, hair follicle, and connective-tissue models. KPV research is concentrated in intestinal epithelium and inflammatory-bowel-disease models.
Why is the GHK-Cu vial larger?
GHK-Cu has a low molecular weight and published research uses larger absolute mass amounts per dose. The 50 mg vial reflects vendor convention.
Are they co-administered in research?
Not in the published literature. The mechanisms are unrelated, but no combined-protocol data exist.
Are either approved for human therapeutic use?
Neither is approved by the FDA or Health Canada as a human therapeutic. Both are sold strictly as research-grade reagents.
References
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. [PMID 18061177]
- Kang YA et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Archives of Dermatological Research, 2009. [PMID 19319546]
- Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. [PMID 26236730]
- Viennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of KPV. Cellular and Molecular Gastroenterology and Hepatology, 2016. [PMID 27458604]
- Pickart L et al. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. [PMID 29986520]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.